{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:43:35Z","timestamp":1791942215783,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.clinthera.2020.08.007","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T16:53:33Z","timestamp":1598633613000},"page":"1975-1982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patient-related Risk Factors for Nausea and Vomiting With Standard Antiemetics in Patients With Cancer Receiving Carboplatin: A Retrospective Study"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3458-8415","authenticated-orcid":false,"given":"Izumi","family":"Nasu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0901-1825","authenticated-orcid":false,"given":"Rena","family":"Shimano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0626-7908","authenticated-orcid":false,"given":"Hitoshi","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-5291","authenticated-orcid":false,"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.08.007_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2020.08.007_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.critrevonc.2016.03.014","article-title":"Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies","volume":"102","author":"Ho","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clinthera.2020.08.007_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-015-0852-1","article-title":"Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary","volume":"21","author":"Takeuchi","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.08.007_bib4","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American society of clinical oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.08.007_bib5","series-title":"Antiemesis. Version 1. NCCN Clinical Practice Guidelines in Oncology","year":"2020"},{"key":"10.1016\/j.clinthera.2020.08.007_bib6","first-page":"303","article-title":"2016 Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting","volume":"25","author":"Einhorn","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2020.08.007_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","article-title":"Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review","volume":"99","author":"Sommariva","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clinthera.2020.08.007_bib8","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdw220","article-title":"Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study","volume":"27","author":"Suzuki","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2020.08.007_bib9","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy","volume":"23","author":"Warr","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.08.007_bib10","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1470-2045(15)00034-0","volume":"16","author":"Schwartzberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2020.08.007_bib11","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1634\/theoncologist.2019-0292","article-title":"A\u00a0nationwide, multicenter registry study of antiemesis for carboplatin-based chemotherapy-induced nausea and vomiting in Japan","volume":"25","author":"Iihara","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2020.08.007_bib12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2014.03.017","article-title":"Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy","volume":"84","author":"Ito","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clinthera.2020.08.007_bib13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.lungcan.2015.11.009","article-title":"Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer","volume":"90","author":"Kusagaya","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clinthera.2020.08.007_bib14","first-page":"4527","article-title":"Clinical efficacy of aprepitant in patients with gynecological cancer after chemotherapy using paclitaxel and carboplatin","volume":"35","author":"Maehara","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clinthera.2020.08.007_bib15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10147-015-0928-y","volume":"21","author":"Yahata","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.08.007_bib16","first-page":"3141","article-title":"Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life","volume":"20","author":"Fern\u00e1ndez-Ortega","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2020.08.007_bib17","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.clinthera.2018.10.004","article-title":"Patient-related risk factors for nausea and vomiting with standard antiemetics in patients with breast cancer receiving anthracycline-based chemotherapy: a retrospective observational study","volume":"40","author":"Kawazoe","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2020.08.007_bib18","first-page":"1139","article-title":"Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial","volume":"27","author":"Tsuji","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2020.08.007_bib19","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","article-title":"Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan","volume":"20","author":"Tamura","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clinthera.2020.08.007_bib20","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/cas.12146","article-title":"Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis","volume":"104","author":"Sekine","year":"2013","journal-title":"Canc Sci"},{"key":"10.1016\/j.clinthera.2020.08.007_bib21","first-page":"807","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy","volume":"19","author":"Warr","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2020.08.007_bib22","first-page":"1171","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy","volume":"18","author":"Hesketh","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2020.08.007_bib23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.08.007_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2020.08.007_bib25","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/cam4.2863","article-title":"A\u00a0randomized trial of nurse-administered behavioral interventions to manage anticipatory nausea and vomiting in chemotherapy","volume":"9","author":"Hunter","year":"2020","journal-title":"Canc Med"},{"key":"10.1016\/j.clinthera.2020.08.007_bib26","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1056\/NEJM198212093072402","article-title":"Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy","volume":"307","author":"Morrow","year":"1982","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820303581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820303581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:55:52Z","timestamp":1758963352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820303581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0149291820303581"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.08.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-related Risk Factors for Nausea and Vomiting With Standard Antiemetics in Patients With Cancer Receiving Carboplatin: A Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}